In a bid to bolster its CNS pipeline, Alkermes has agreed to acquire Rodin Therapeutics in a deal worth up to US$950 M. With the deal, Alkermes will gain access to Rodin’s brain-permeable therapeutics that selectively inhibit the HDAC-CoREST (histone deacetylase co-repressor of repressor element-1 silencing transcription factor) complex which is believed to reactivate neuronal gene expression, strengthen existing synapses and promote the creation of new synapses, while minimising known safety concerns for drugs of this class.